id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
cord-284208-8fsqgkw5	Zolla, Lello	Proteomics studies reveal important information on small molecule therapeutics: a case study on plasma proteins	2008-11-07		.txt	text/plain	6995	245	30	HUPO plasma proteome project: challenges and future directions The human proteome organization plasma proteome project pilot phase: reference specimens, technology platform comparisons, and standardized data submissions and analyses Characterization of the human blood plasma proteome Utilizing human blood plasma for proteomic biomarker discovery Oxidation of proteins: basic principles and perspectives for blood proteomics Proteomic analysis of RBC membrane protein degradation during blood storage Composition of the peptide fraction in human blood plasma: database of circulating human peptides Peptide and protein drug delivery to and into tumors: challenges and solutions Effects of genetic engineering on the pharmacokinetics of antibodies Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry Multi-component immunoaffinity subtraction chromatography: an innovative step towards a comprehensive survey of the human plasma proteome Differences among techniques for high-abundant protein depletion Immunoaffinity separation of plasma proteins by IgY microbeads: meeting the needs of proteomic sample preparation and analysis Evaluation of multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry A novel four-dimensional strategy combining protein and peptide separation methods enables detection of low-abundance proteins in human plasma and serum proteomes Two-dimensional separation of human plasma proteins using iterative free-flow electrophoresis The ProteoMiner in the proteomic arena: a non-depleting tool for discovering low-abundance species Prefractionation, enrichment, desalting and depleting of low volume and low abundance proteins and peptides using the MF10 An investigation into the human serum interactome Protein biomarker discovery and validation: the long and uncertain path to clinical utility Proteomics and disease -the challenges for technology and discovery Clinical proteomics: revolutionizing disease detection and patient tailoring therapy Mining the plasma proteome for cancer biomarkers Strategies for plasma proteomic profiling of cancers Proteomics-driven cancer biomarker discovery: looking to the future Dysregulation of retinoid transporters expression in body fluids of schizophrenia patients Comparative plasma proteome analysis of lymphoma-bearing SJL mice Proteomic characterization of inter-alpha inhibitor proteins from human plasma Proteomic strategies for Individualizing therapy of acute myeloid leukemia (AML) Pharmacogenomics and pharmacoproteomics in the evaluation and management of short stature From genomics to proteomics Mass spectrometry-based proteomics Mass spectrometry-based clinical proteomics Calorimetry outside the box: a new window into the plasma proteome The impact of systems approaches on biological problems in drug discovery Identifying pharmacodynamic protein markers of centrally active drugs in humans: a pilot study in a novel clinical model Alpha cell function in health and disease: influence of glucagon-like peptide-1 Technologies and methods for sample pretreatment in efficient proteome and peptidome analysis Quantitative phosphoproteomic analysis of signaling network dynamics Signaling -2000 and beyond Technology insight: pharmacoproteomics for cancerpromises of patient-tailored medicine using protein microarrays High-content single-cell drug screening with phosphospecific flow cytometry Antibody arrays in cancer research Protein chip technology Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front Progress in protein and antibody In the near future, pharmacoproteomics, the use of proteomic technologies in the field of drug discovery and development, and interactomics, the branch of proteomics which is concerned with identifying interactions between proteins, will allow researchers to (i) know the specific protein changes that occur in biological compartments in response to drug administration; (ii) design small novel therapeutic molecules that can have extended half-lives if carried by plasma protein in the blood stream.	cache/cord-284208-8fsqgkw5.txt	txt/cord-284208-8fsqgkw5.txt
